Loading
Life sciences · Journal article
Bioconjugate Chemistry · September 21, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract In vivo characterization and visualization of tumors often relies on radioactive tracers and expensive, complex equipment, which limits the frequency of analysis, throughput, and accessibility. Short-wave infrared (SWIR) fluorescence is a new nonradioisotopic imaging modality with flexible readouts at high depth and high signal-to-background contrast. Here, we report semiconductor quantum dots (QDs) with SWIR fluorescence engineered to selectively target tumor-associated macrophages (TAMs) by functionalization with the polysaccharide dextran (Dex). TAMs are often abundant in the tumor microenvironment and mediate immune suppression, angiogenesis, metastatic progression, and therapy resistance, making them important targets for in situ analysis. We compare QD-Dex probes with QDs coated with polyethylene glycol (QD-PEG) as nontargeted controls with equivalent fluorescence, hydrodynamic size, and electrostatic charge. In vitro, QD-Dex exhibited receptor-mediated uptake by cultured macrophages whereas QD-PEG uptake was only through noncompetitive passive processes. In vivo, SWIR imaging of immunocompetent mice bearing TAM-rich orthotopic 4T1 mammary tumors revealed tumor retention of QD-Dex after intravenous administration. Tumor signals for QD-PEG were much lower in comparison. Tumor signals for QD-Dex exceeded blood levels ∼2 h after injection and decayed substantially after 24 h, providing an appropriate time window for preclinical imaging studies in rodents. These findings establish baseline metrics for macrophage-targeted SWIR nanoprobes as a platform for preclinical in vivo tumor analysis without ionizing radiation.